Liposomal oligonucleotide compositions for modulating RAS gene e

Details Liposomal oligonucleotide compositions for modulating RAS gene e Liposomal oligonucleotide compositions for modulating RAS gene e

1997-10-31

2000-07-04

Degen, Nancy

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

435 6, 435455, 435375, 435377, 536 231, 536 241, 536 245, A61K 4800, C07H 2104, C07H 2102, C12N 1511

Patent

active

060839236

ABSTRACT:
Pharmaceutical compositions comprising sterically stabilized liposomes containing antisense oligonucleotides are provided for the modulation of expression of the human ras gene in both the normal (wildtype) and activated (mutant) forms.

REFERENCES:
patent: 4426330 (1984-01-01), Sears
patent: 4534899 (1985-08-01), Sears
patent: 4837028 (1989-06-01), Allen
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5527528 (1996-06-01), Allen et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5556948 (1996-09-01), Tagawa et al.
patent: 5576208 (1996-11-01), Monia et al.
patent: 5582972 (1996-12-01), Lima et al.
patent: 5582986 (1996-12-01), Monia et al.
patent: 5593974 (1997-01-01), Rosenberg et al.
patent: 5661134 (1997-08-01), Cook et al.
patent: 5665710 (1997-09-01), Rahman et al.
Uhlmann et al. "Antisense Oligonucleotides: A New Therapeutic Principle" Chemical Reviews vol. 90(4):543-584, Jun. 1990.
Agrawal, S. "Antisense Oligonucleotides: Towards Clinical Trials" TIBTECH vol. 14:376-387, Oct. 1996.
Branch, A. "A Good Antisense is Hard to Find" TIBS vol. 23:45-50, Feb. 1998.
Chang et al. "Antisense Inhibition of ras p21 Expression that is Sensitive to a Point Mutation" Biochemistry vol. 30(34):8283-8286, Aug. 27, 1991.
Allen et al., "Large unilamellar liposomes with low uptake into the reticuloendothelial system", FEBS Letters 223:42, 1987.
Blume et al., "Liposomes for the sustained drug release in vivo", Biochimica et Biophysica Acta 1029:91, 1990.
Chonn et al., "Recent advances in liposomal drug-delivery systems", Current Op. Biotech. 6:698, 1995.
Cossum et al., "Disposition of the .sup.14 C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Rats", J. Pharmacol. Exp. Therap. 267:1181, 1993.
Dean et al., "Inhibition of Growth of Human Tumor Cell Lines in Nude Mice by an Antisense Oligonucleotide Inhibitor of Protein Kinase C-.alpha. Expression" Cancer Res. 56:3499, 1996.
Dean et al., "Inhibition of protein kinase C-.alpha. expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides", Proc. Natl. Acad. Sci. U.S.A. 91:11766, 1994.
Downward, "The ras superfamily of small GTP-binding proteins", Trends Biochem. Sci. 15:469, 1990.
Gabizon et al., "Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors", Proc. Natl. Acad. Sci. U.S.A. 85:6949, 1988.
Illum et al., "The organ uptake of intravenously administrered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338)", FEBS Letters 167:79, 1984.
Klibanov et al., "Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes", FEBS Letts. 268:235, 1990.
Marshall, "The effector interactions of p21.sup.ras ", Trends Biochem. Sci. 18:250, 1993.
Papahadjopoulos et al., "Targeting of Liposomes to Tumor Cells in Vivo.alpha.", Ann. N.Y. Acad. Sci., 308:64, 1978.
Papahadjopoulos et al., "Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy", Proc. Natl. Acad. Sci. U.S.A. 88:11460, 1991.
Sunamoto et al., Liposomal Membranes. V. Interaction of Zinc(II) Ion with Egg Phosphatidylcholine Liposomes, Bull. Chem. Soc. Jpn. 53:2778, 1980.
Weinberg, "How Cancer Arises", Sci. American 275:62 1996.
Wu et al., "Increased Microvascular Permeability Contributes to Preferential Accumulation of Stealth.sup.1 Liposomes in Tumor Tissue.sup.2 ", Cancer Research 53:3765, 1993.
Agrawal et al., "Pharmacokinetics of Antisense Oligonucleotides", Clinical Pharmacokinet. 28:7, 1995.
Davies et al., "Physiological Parameters in Laboratory Animals and Humans", Pharm. Res. 10:1093, 1993.

Affiliated with

Also associated with

Rating

Liposomal oligonucleotide compositions for modulating RAS gene e does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposomal oligonucleotide compositions for modulating RAS gene e, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal oligonucleotide compositions for modulating RAS gene e will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1486695